Answering important questions about human disease mechanism, diagnosis and therapy requires that molecular tools be coupled effectively to detailed clinical phenotyping, particularly in patients followed prospectively over time. Bioassay Core (Core B) is designed to serve the Research Base as a centralized resource for standardized preparation and storage of clinical samples, and for conducting a range of high quality, low-cost assays on clinically derived material. The latter will include both assays performed using commercial kits, as well as custom-designed assays. In the past 5 years, the Bioassay Core has proven its ability to serve the Research base by providing crucial biospecimens and assays for numerous peer reviewed publications, abstracts, and investigator-initiated grant proposals.
The aim of this proposal is to continue growing this critical resource which fuels innovation, collaboration and facilitiates studies focused on a wide range of rheumatic diseases by researchers across the spectrum of investigation. Major services and assays that will be provided by the Bioassay Core include sample preparation (eg, serum, DNA, RNA, PBMCs), storage and retrieval, as well as ELISAs, autoantibody analyses and immunohistochemistry. The Core will also help to connect investigators to other appropriate institutional Cores, and participate in outreach activities. Core B will also provide training, management and quality control to staff in the Clinical Centers to ensure that best practice standards for processing, recordkeeping, and ensuring fidelity of labeling are uniformly applied, and to aid Investigators to take any custom assays established in the Core back to their own labs. The Core will be led by Dr. Livia Casciola-Rosen, who has been Director of this project for the past 3 years, and has many years experience in immunology and assay development. Additional leadership will be provided by Dr. Felipe Andrade and Dr. Laura Gutierrez. The availability of central systems to facilitate sample collection, processing, storage and assays has been critical to enabling scholarship on human rheumatic disease cohorts. The close coordination of this Core with the Administrative, Flow Cytometry and Human Subjects Research and Analytical Cores provides an extremely powerful matrix to maximize synergies in the environment.
This Bioassay Core provides systems and infrastructure to enhance research on humans with autoimmune rheumatic diseases. Collection of samples, and their processing, storage, transport, and assay, in a highly standardized way, provides economy of scale and uniform quality difficult to achieve by individual investigators working alone. It will also facilitate the connection of investigators, collaborators and techniques that they could not easily access alone.
|Needham, Dale M; Sepulveda, Kristin A; Dinglas, Victor D et al. (2017) Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study. Am J Respir Crit Care Med 196:1122-1130|
|Darrah, Erika; Kim, AeRyon; Zhang, Xi et al. (2017) Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis. J Proteome Res 16:355-365|
|Cappelli, Laura C; Naidoo, Jarushka; Bingham 3rd, Clifton O et al. (2017) Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy 9:5-8|
|Pinal-Fernandez, Iago; Parks, Cassie; Werner, Jessie L et al. (2017) Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken) 69:263-270|
|Baer, Alan N; Petri, Michelle; Sohn, Jungsan et al. (2017) Reply. Arthritis Care Res (Hoboken) 69:454|
|Adler, Brittany L; Albayda, Jemima; Shores, Jamie T et al. (2017) Erosive Rheumatoid Arthritis After Bilateral Hand Transplantation. Ann Intern Med 167:216-218|
|Cappelli, Laura C; Gutierrez, Anna Kristina; Baer, Alan N et al. (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43-50|
|Albayda, Jemima; Pinal-Fernandez, Iago; Huang, Wilson et al. (2017) Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken) 69:1771-1776|
|Cappelli, Laura C; Shah, Ami A; Bingham 3rd, Clifton O (2017) Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Am 43:65-78|
|Turnbull, Alison E; Sepulveda, Kristin A; Dinglas, Victor D et al. (2017) Core Domains for Clinical Research in Acute Respiratory Failure Survivors: An International Modified Delphi Consensus Study. Crit Care Med 45:1001-1010|
Showing the most recent 10 out of 108 publications